High uric acidemia huge market, Haitron URAT1 new drug started the first phase of clinical;

original title: high uric acidemia huge market, Haitron URAT1 new drug started a clinical phase, a number of domestic research, Chengdu Haitron1Drug melt data, PharnexDatamonitor data monitoring shows: May 2019, from Chengdu Haitron Pharmaceutical Co., Ltdbid for the "Chinese health subjectoral HP501 The phase I study on the safety, tolerance, pharmacokinetics (PK) and pharmacodynamics (PD) of single-release tablets and the effects of non-bustas tablets and the effects of food was approved by the Genetic office2Clinical Trial Registration:Registration Number:CTR20190247Indications:high uric acidemiatrial popular topic:HP501 Reprieve Phase I Clinical TrialTrial Professional Topic:China Health Subject synopsis HP501 Slow Release Tablet Single and Multiple Administration Safety, Tolerance Study The Phase I study and evaluation of drug interactions and food effectstrial program number:501-CHN-001, V1.1
HP501 is a new class 1 new drug developed by Haitron Pharmaceuticals for the treatment of hyperulitimics and gout, according to preclinical studies, its biological activity is superior to similar drugs3Patents for related gout, hyperuric acid drugs:CN105294585B_ a compound that treats gout; CN108863919A_ sulfonamide compounds and their preparation methods for the treatment of gout or hyperuric acidemia; CN106831556A_ sulfonamide compounds and their preparation methods and uses as urea transport inhibitors; CN106831569A_ of niphthaands and their preparation methods and their use as urea transport inhibitors;4Hinovapharma PipelineThe fastest progress at present is the thorium-en-heloamine, the clinical phase III has begunThe first patient was added to the group in Aprilsecond, domestic gout, high uric acidemia new drugs in the research enterprise1SHR4640, URAT1 inhibitor class from Hengrui Pharmaceuticals, is used for hyperuric acidemia and goutCurrently in phase II clinical phase;2 Jiangsu New Elemental Medicine, URAT1 inhibitors (relevant patents: CN108084186A_URAT1 inhibitors and their applications, URAT1 inhibitors CN108484600A_ uric acid excretion, etc.), ABP-671 filed an IND application with the FDA in September 2018 and obtained FDA approves Phase I clinical trials in the U.S.; 3.TWiBiotechnology's small molecule drug AC-201 (URAT1 inhibitor); 4.Tianjin Pharmaceutical Research Institute, CN108658879A, a URAT1 inhibitor and its preparation methods and uses; Other enterprises are Haizheng Pharmaceuticals, Jiangsu Ai Likang Pharmaceuticals and so on three, from a global perspective
the current field of gout / hyperuric acidemia new drug research and development is mainly concentrated in the niobium metabolism key enzymes or URAT1 as the target of the three directions of uric acid and uric acid oxidase, the three directions, in the study of drugs relatively few 4, the large number of people with diseases
data show that the prevalence of hyperuric acidemia in Chinese adults is 8.4% to 13.3%, middle-aged and elderly men and postmenopausal women are high-risk population, the trend of youth intensified With the increase of blood uric acid level, the prevalence of gout also increases According to epidemiological surveys, the prevalence of gout in China is about 1.1%, and the number of cases is about 16 million, mainly due to recurrent episodes of severe joint pain domestic current use of more drugs for non-bustam, puritanol and phenyl brominated maron, autumn daffodils and so on reference: NMPA/CDE; Pharmaceutical Melt data, Pharnex Datamonitor; Pharmaceutical melting public disclosure by related companies; etc